MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Pimavanserin Safety in Adult and Elderly Patients With Neuropsychiatric Symptoms Related to Neurodegenerative Disease: an Open-Label Extension Study

    W. Cubała, A. Berrio, K. Chi-Burris, G. Alva, L. Chrones, S. Pathak (Gdańsk, Poland)

    Objective: To assess the long-term safety and tolerability of pimavanserin in frail older adults and elderly patients with neuropsychiatric symptoms related to a neurodegenerative disease…
  • 2024 International Congress

    Design, synthesis and pharmacological evaluation of 16-pyridylmethylene derivatives of steroidal oximes as antiparkinsonian agents in MPTP-injected mice.

    R. Singh, R. Bansal (Chandigarh, India)

    Objective: The objective of the present study is focused on the design and synthesis of 16-pyridyl methylene derivatives of steroidal oximes and further their pharmacological…
  • 2024 International Congress

    Effects of ATH434, a Clinical-Phase Small Molecule with Moderate Affinity for Iron, in a Parkinson’s Disease Model in Macaques

    M. Bradbury, M. Aumann, D. Claassen, D. Finkelstein (Newark, USA)

    Objective: (1) Determine whether oral ATH434 improves motor performance in a non-human primate hemiparkinasonian model when administered after symptom onset. (2) Relate observations to changes…
  • 2024 International Congress

    Comparing Pramipexole and Ropinirole in the management of the tremor in Parkinson’s disease in the low-income country and environment of restricted medications.

    B. Mukhammedaminov (Uzbekistan, Uzbekistan)

    Objective: To inform the world community about the state situation on Parkinson’s disease in Uzbekistan. Objective: To Co inform the world community about the state…
  • 2024 International Congress

    Real-World Multicenter Analysis of Levodopa Equivalent Daily Dosage Algorithms- Capturing Geographical and Demographic Disparities in Parkinson’s Disease Therapy Spanning Six Countries and Two Continents

    P. Kukkle, L. Kalia, A. Habib, P. Jagota, R. Ojha, R. Kandadai, S. Desai, M. Caldera, D. Sirisena, D. Garg, T. Mestre, R. Neupane, S. Maytharakcheep, K. Sanyawut, R. Borgohain (Bangalore, India)

    Objective: To assess the influence of updated Levodopa Equivalent Daily Dosage (LEDD) conversion factors in capturing the newer therapies in Parkinson’s Disease (PD) and therapy…
  • 2024 International Congress

    Recruitment of Ethnoracially Diverse Participants for Disease-Modifying Drug Trials in Parkinson’s Disease: Are We Doing It Right? A Systematic Review and Meta-Analysis.

    F. Reis Rodrigues, E. Pasqualotto, G. Ribeiro, J. M. Couto, E. Bayram, M. Ushe, D. Di Luca (Vicosa, Brazil)

    Objective: To perform a systematic review and meta-analysis on recruitment of people with Parkinson’s disease (PwP, PD) from different ethnic and racial groups in disease-modifying…
  • 2024 International Congress

    Buspirone/zolmitriptan combination exerts synergistic reduction in dyskinesia without worsening Parkinson disease motor symptomatology

    P. Lewitt, G. Stebbins, K. Christensen, M. Thomsen, R. Tan, A. Pretorius (Detroit, USA)

    Objective: Levodopa-induced dyskinesias (LID) may be amenable to interventions with striatal serotonergic receptors. Preclinical evidence suggests that co-administration of serotonergic agonists with selective receptor properties…
  • 2024 International Congress

    ECAP-Controlled Closed-Loop SCS Alleviates Neuropathic Pain and Improves Motor Function in a Patient Suffering from Parkinson’s Disease and Radicular Pain

    Z. Zamfirov, D. Mugan, G. Ahluwalia (Annapolis, USA)

    Objective: The objective of this case report is to highlight the effect of a new technology, Evoked Compound Action Potential (ECAP) controlled closed-loop spinal cord…
  • 2024 International Congress

    Alpha-synuclein affects PRMT5-mediated cytoprotective pathway in neuronally differentiated SH-SY5Y cell

    T. Nakamura, N. Sugeno, T. Hasegawa, K. Ikeda, S. Yoshida, S. Ishiyama, K. Sato, A. Takeda, M. Aoki (Sendai, Japan)

    Objective: To explore the impact of α-synuclein (αS) on PRMT5. Background: Alpha-synuclein (αS) is recognized as the pivotal molecule in the pathomechanism of Parkinson's disease.…
  • 2024 International Congress

    Investigating the pathogenesis of GBA1-associated Parkinson’s disease using GBA1 isogenic iPSC lines

    Y. Chen, C. Chen, C. Ma, J. Lichtenberg, E. Hertz, T. Jong, R. Sam, Y. Li, S. Vrisjen, P. Vangheluwe, C. Blauwendraat, E. Sidransky (Bethesda, USA)

    Objective: We aim to explore the pathogenesis of GBA1-associated synucleinopathies and discern the gain- vs. loss-of-function hypotheses by genetically engineering GBA1 in an iPSC line derived…
  • « Previous Page
  • 1
  • …
  • 161
  • 162
  • 163
  • 164
  • 165
  • …
  • 181
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Welcome to the MDS Abstracts Site
    • Effect of marijuana on Essential Tremor: A case report
    • Advanced Search
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley